|
Steffen, K. (1993). Folienrauchen – ein zeitgeschichtliches Dokument : Ausschnitte aus einem Interview mit zwei FolienraucherInnen in Zürich. Drogalkohol : Alkohol und Drogen : Forschung und Praxis der Prävention und Rehabilitation, 17(2), 115–122.
|
|
|
Donoghoe, M. C., & Power, R. (1993). Household bleach as disinfectant for use by injecting drug users. The Lancet, 341(26.06.1993), 1658.
|
|
|
Hendriks, V. M., van den Brink, W., Blanken, P., Bosman, I. J., & van Ree, J. M. (2001). Heroin self-administration by means of “chasing the dragon” : pharmacodynamics and bioavailability of inhaled heroin. European Neuropsychopharmacology, 11, 241–252.
|
|
|
Rhodes, T., & Quirk, A. (1995). Where is the sex in harm reduction. International journal of drug policy, 6, 78–82.
|
|
|
Somaini, B., Wang, J., Perozo, M., Kuhn, F., Meili, D., Grob, P., et al. (2000). A continuing concern : HIV and hepatitis testing and prevalence among drug users in substitution programs in Zurich, Switzerland. AIDS Care, 12(4), 449–460.
Abstract: Phase I of the Zurich Prometheus Study is a cross-sectional study focusing on an up-to-date serology for HIV and hepatitis B/C and associated risk factors for all clients in four participating clinics offering opiate substitution in Zurich, Switzerland. The mean age of the 603 respondents is 30.7 years (SD=6.2), and 38% of them are women. Seventy-five percent of the respondents have a history of injecting drug use (IDU), and over half have injected within the past six months. Lab-confirmed seroprevalence for HBV (50%) and HCV (57%) is twice that of HIV (24%). There is an 80% risk reduction for all three viral infections among those starting IDU after 1991—when harm reduction efforts were in full swing—compared to those who began before 1988—before clean needles were widely available. These findings suggest a strongly protective effective of harm reduction measures. But while a stabilization in HIV prevalence at 15% can be seen among drug users who started injecting after 1991, prevalence rates for HBV and HCV still remain several times higher. The prevalence data in this study support data showing continued high incidence rates for HBV and HCV, even among new injectors in the harm reduction era.
Keywords: health promotion
|
|
|
Edlin, B. R., Seal, K. H., Lorvick, J., Kral, A. H., Ciccarone, D. H., Moore, L. D., et al. (2001). Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? The New England journal of medicine, 345(3; 19.07.2001), 211–214.
Keywords: health promotion; viral hepatitis; hepatitis C
|
|
|
Feyerabend, E. (1999). Um die Wette geimpft. Bioskop, (7; 09/1999), 8–9.
Keywords: health promotion; viral hepatitis; hepatitis B
|
|
|
Bousingen, D. D. de. (2001). Drug firm compensates patients for suspected hepatitis B vaccine failure. The Lancet, 357(19.05.2001), 1598.
Abstract: A French appeal court has ordered GlaxoSmithKline (GSK) to pay US$6686 and US$10 697 in compensation to two women with multiple sclerosis who claim the chronic disease was caused by a hepatitis B vaccine (Engerix B) manufactured by the pharmaceutical company.
Keywords: health promotion; viral hepatitis; hepatitis B
|
|
|
Balthasar, H., Huissoud, T., Zobel, F., Arnaud, S., Samitca, S., Jeannin, A., et al. (2007). Evolution de la consommation et des pratiques à risques de transmission du VIH et du VHC chez les consommateurs de drogue par injection en Suisse, 1993-2006. Bulletin, (45; 05.11.2009), 804–809.
Keywords: HIV infection; Aids; Switzerland; journal article
|
|
|
Charrat Diop, L. (2008). Grisélidis : Outreach-Organisation für Sexworkerinnen in Fribourg. Swiss Aids News : Medizin, Gesellschaft, Recht, (1; 02/2008), 1.
Keywords: harm reduction; Aids; HIV infection; health promotion; prostitution
|
|